Skip to main content
. 2016 Jun 22;36(2):626–632. doi: 10.3892/or.2016.4902

Figure 4.

Figure 4

Combination therapy suppresses tumor cell-derived VEGF and galectin-3 in tumor tissues. (A) Membranes-based antibody arrays were reacted with tumor tissue homogenates from the control group, bevacizumab group, capecitabine group, and combination group on day 50. (B) Levels of free VEGF in the tumor tissues (n=7). (C) Levels of galectin-1 and galectin-3 in the tumor tissues (n=7). The control group (open), bevacizumab group (horizontal striped), capecitabine group (hatched), and combination group (closed). Columns show mean ± SD. aP<0.05 versus control by Wilcoxon test. (D) Downregulation of galectin-3 expression by 5-FU in in vitro culture. Culture supernatant was collected and subjected to ELISA (n=3). Columns show mean ± SD. aP<0.05 versus control by Dunnett's test.